Overall rank by patents
#2,670
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Sangamo Therapeutics, Inc.
USPTO PatentsView assignee record — 146 granted patents across 14 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
146
Total patents granted
14
CPC technology areas
12.3
Avg claims per patent
+35%
5-year filing velocity
The verdict
Sangamo holds 146 US patents across 14 technology areas — rank #2,670 of 50,000 tracked assignees.
- #2,670
- of 50,000 US assignees by volume
- Top 32%
- by Innovation Score (41.8/100)
- 12.3
- avg claims per patent
- +35%
- filing velocity, last 5 yrs
Portfolio overview
Sangamo Therapeutics, Inc. has been granted 146 US utility patents between 2017 and 2025, placing Sangamo Therapeutics, Inc. at rank #2,670 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.3 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Sangamo Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 41.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 84 grants, compared with 62 in the 2015–2019 window — a +35% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Sangamo Therapeutics, Inc.'s 12.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sangamo Therapeutics, Inc. against peers pursuing similar technology classes.
How does Sangamo compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Sangamo Therapeut… ◀ 146
Sangamo Therapeutics, Inc.
146 patents
What this shows Sangamo holds 146 patents — placing it at rank #2,670 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Sangamo's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
42 Top 32% higher than 68% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2017–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 13 | 8.9% |
| 2018 | 26 | 17.8% |
| 2019 | 23 | 15.8% |
| 2020 | 24 | 16.4% |
| 2021 | 20 | 13.7% |
| 2022 | 14 | 9.6% |
| 2023 | 18 | 12.3% |
| 2024 | 7 | 4.8% |
| 2025 | 1 | 0.7% |
Which technologies does Sangamo Therapeutics, Inc. patent most?
C07K— PEPTIDES 108
Top 14 of 14 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Standard
Velocity Growing
Frequently Asked Questions
How many patents does Sangamo Therapeutics, Inc. hold?
Sangamo Therapeutics, Inc. holds 146 US granted patents filed between 2017 and 2025, spanning 14 technology areas.
What is Sangamo Therapeutics, Inc.'s Innovation Score?
Sangamo Therapeutics, Inc. has an Innovation Score of 41.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Sangamo Therapeutics, Inc. focus on?
Sangamo Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 143 patents. The company has filed patents in 14 CPC subclasses total.
Is Sangamo Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Sangamo Therapeutics, Inc.'s recent filing velocity is +35% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Sangamo Therapeutics, Inc.'s patents?
Sangamo Therapeutics, Inc.'s patents average 12.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Sangamo Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
Explore the patent dataset
C12N technology
Sangamo Therapeutics, Inc.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Sangamo Therapeutics, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
- USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
- USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
- USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
- SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
- WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope
